nafamostat has been researched along with Encephalopathy, Hepatic in 1 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ogawa, M | 1 |
| Mori, Y | 1 |
| Ueda, S | 1 |
| Mori, T | 1 |
| Makino, Y | 1 |
| Hori, J | 1 |
| Ohto, M | 1 |
| Wakashin, M | 1 |
1 other study available for nafamostat and Encephalopathy, Hepatic
| Article | Year |
|---|---|
Protective effects of FUT-175 on acute massive hepatic necrosis induced in mice following endotoxin injection and immunization with liver proteins.
Topics: Acute Disease; Animals; Autoimmune Diseases; Benzamidines; Chemical and Drug Induced Liver Injury; E | 1993 |